ABPI WELCOMES TRADE MARK REFORM
The Association of the British Pharmaceutical Industry has welcomed the new Trade Marks Bill, which is intended to simplify the current complex trade mark situation in the UK.
The Department of Trade and Industry estimates that the new legislation could save British industry some L 60 million ($88.8 million) in its first year and L 30 million a year thereafter.
The main provisions of the bill will make it easier for a trade mark to qualify for registration, provide wider infringement rights, enable the UK to ratify the Madrid Protocol on registration of trade marks, deregulate procedures, improve measures against counterfeiting and abolish the complex legal problems associated with the previous legislation, says the DTI.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze